INTRODUCTION {#s1}
============

Niemann--Pick represents a group of progressive neurodegenerative diseases characterized by defects in lipid metabolism. Typically, Niemann--Pick disease type A presents in infancy, whereas type B presents in mid-childhood. In contrast, type C disease is marked by greater variability in timing, both of presentation and eventual demise. The progression of neurological abnormalities typically begins with ataxia and frequently includes spasticity and seizures. Dystonia, vertical supranuclear gaze palsy, dementia, and psychiatric manifestations are also common.

At the cellular level, Niemann--Pick disease type C (NPC) is characterized by defects in cholesterol storage and esterification. Consistent with this, *NPC1* and *NPC2* are believed to function in a coordinated fashion in the endosomal processing of cholesterol, as well as other lipids ([@DOUGHERTYMCS001222C41]). Specifically, cells cultured from patients with NPC were found to have a severe deficit in cholesterol esterification, whereas this process remains intact in cells from Niemann--Pick type A and B patients ([@DOUGHERTYMCS001222C34]). As such, the diagnosis of NPC traditionally included a cholesterol esterification assay from cultured fibroblasts, as well as filipin staining to demonstrate excess intracellular cholesterol. Recently, the search for blood-based tests for biomarkers has yielded a number of diagnostic metabolites that can be detected sensitively and measured accurately by mass spectrometry (for review, see [@DOUGHERTYMCS001222C42]). These include the cholesterol oxidation product cholestane-3β,5α,6β-triol, which appears to be elevated because of the combination of increased oxidative stress and deposition of free cholesterol in NPC ([@DOUGHERTYMCS001222C35]), as well as bile acid metabolites 3β-hydroxy-7β-*N*-acetylglucosaminyl-5-cholenoic acid and *N*-(3β,5α,6β-trihydroxy-cholan-24-oyl)glycine, which have the potential to be used as part of a newborn screen because of their detectability in dried blood spots ([@DOUGHERTYMCS001222C17]; [@DOUGHERTYMCS001222C25]). Mutations in *NPC1* account for 95% of patients with NPC, with the remainder coming from *NPC2* ([@DOUGHERTYMCS001222C41]). Within *NPC1* and *NPC2*, a wide spectrum of DNA sequence variants can cause clinically significant disease; more than 150 known causal mutations have been identified in *NPC1* alone ([@DOUGHERTYMCS001222C15]; [@DOUGHERTYMCS001222C1]).

The adult-onset form of the disease, which is believed to comprise ∼10% of cases, typically presents in the second or third decade with neurological symptoms. Recent predictions of the frequency of disruptive mutations in *NPC1* and *NPC2* from large exome data sets suggest that the incidence of the more easily missed adult-onset form may be more common than previously thought ([@DOUGHERTYMCS001222C45]). Given the variable disease presentation and incomplete understanding of the spectrum of variation that can cause NPC, it is important to understand how a patient-specific mutation in NPC1 as well as modifying genetic factors contribute to phenotypic heterogeneity.

Even in highly penetrant Mendelian diseases, variability in phenotype can be a result of both differences at the disease locus and modifiers elsewhere in the genome. Cystic fibrosis (CF) patients with the compound heterozygous *CFTR* genotype R117H/ΔF508 show a less severe phenotype than those homozygous for ΔF508, including later diagnosis and lower sweat chloride concentration ([@DOUGHERTYMCS001222C40]). At the same time, genome-wide association studies in CF patients have uncovered modifier loci in relevant pathways outside of *CFTR* influencing the severity of lung disease ([@DOUGHERTYMCS001222C9]). Thus, variation elsewhere in the genome can exert significant effects on disease severity.

In this study, we present the case of a patient who died of adult-onset NPC, including a "genomic autopsy" from whole-genome sequencing (WGS) performed posthumously. We sought to determine if the unusually late onset and long survival of the patient could be accounted for by his previously identified variants in *NPC1* alone or if there were other genetic modifiers that contributed to his phenotype. We provide supporting evidence that the variant V950M (rs120074135) causes a milder deficit in *NPC1* function and as such is responsible for both the patient\'s relatively high cholesterol esterification levels and longevity.

RESULTS {#s2}
=======

Clinical Presentation {#s2a}
---------------------

The patient was a 54-yr-old man who had apparently enjoyed good health until he presented to a brain injury clinic at the age of 20 complaining of inability to maintain jobs and difficulty controlling finances, which he had attributed to two separate blows to the head from a baseball. He did not experience additional neurological symptoms with either incident and was clinically and radiologically cleared at the time. His mother described a slightly earlier onset of progressive symptoms, around the age of 18, which included increasing incidents of tripping and falling, poor concentration, memory difficulties, and worsening speech articulation. Further investigation revealed a history of neonatal jaundice and hepatomegaly, prompting bone marrow biopsy, which showed evidence of a lipid storage disease consistent with either Gaucher\'s or Niemann--Pick disease. Neonatal symptoms abated, and the findings were not pursued further. The patient was referred to the medical genetics clinic where physical examination revealed splenomegaly, mild speech slurring, apparent restriction of vertical saccades, and trace gait instability. β-Glucosidase enzyme activity was normal, excluding Gaucher\'s disease. Skin punch biopsy showed ultrastructural evidence of intracellular lipid storage disorder, and a cholesterol esterification assay was abnormal, indicating NPC. Interestingly, his level of intracellular cholesterol esterification was higher than the average patient with NPC at 357 (normal: 3342 ± 1729; disease: 90 ± 140), meriting his biochemical classification as "variant" NPC.

Therapy with a cholesterol-lowering agent (lovastatin) and a reduced-cholesterol diet was initiated early in his course. He entered an experimental treatment trial with OGT 918 (miglustat) at approximately age 42. His disease was relatively stable with slow progression of findings that included increasing dysarthria, hearing loss, decreased gag reflex, cognitive and behavioral issues, and continued coordination problems with increasing falls (after age 45). His ataxia and spasticity rendered him nonambulatory, and he continued to have increasingly frequent falls out of bed complicated by subdural hemorrhage along with ongoing dysphagia with chronic aspiration. He had an aspiration event requiring hospital admission and was transferred to hospice care, expiring ∼1 mo later. Of interest, his younger brother by 2 yr has also been diagnosed with NPC and has followed a similar course.

Genomic Analyses {#s2b}
----------------

At the *NPC1* locus, the patient was positive for heterozygous V950M (rs28942105) and N1156S (rs120074135) missense mutations, each of which is known to be associated with NPC ([Fig. 1](#DOUGHERTYMCS001222F1){ref-type="fig"}; [@DOUGHERTYMCS001222C6]; [@DOUGHERTYMCS001222C28]). The V950M mutation has been seen previously in the homozygous form as well as in conjunction with an I1061T mutation ([@DOUGHERTYMCS001222C38]). The I1061T mutation by itself is often seen in patients with milder disease phenotypes: It is associated with a slowly progressive juvenile form of the disease and was common in a set of adult-onset NPC ([@DOUGHERTYMCS001222C27]; [@DOUGHERTYMCS001222C38]). On the other hand, the N1156S mutation was previously found to lead to severe infantile disease in conjunction with a Q775P mutation ([@DOUGHERTYMCS001222C13]). Sanger DNA sequencing of *NPC1* confirmed that the patient\'s brother, who had a very similar clinical presentation and disease course, carried the same *NPC1* coding mutations. With genotype data from the patient\'s parents unavailable, we cannot say for certain if these occur on the same haplotype; however, a *trans* orientation is most likely given the recessive nature of NPC.

![Location of NPC1 variants. Highlighted are the locations of the patient\'s two disease-causing variants: 950V/M sits in luminal domain I, the third large luminal domain of NPC, whereas 1156N/S sits in the 11th transmembrane domain, in a region with homology to the patched family of proteins.](DoughertyMCS001222_F1){#DOUGHERTYMCS001222F1}

Including the V950M and N1156S mutations, the patient possessed five total missense variants and two synonymous variants in the coding region of *NPC1*, one 5′-UTR variant ([Table 1](#DOUGHERTYMCS001222TB1){ref-type="table"}) and 51 single-nucleotide variants (SNVs) and 10 small indels in the gene\'s intronic regions. The three additional missense mutations, H215R, M642I, and I858V, are considered to be benign: They are highly polymorphic and have been demonstrated to occur in equal abundance in both affected and nonaffected individuals ([@DOUGHERTYMCS001222C27]; [@DOUGHERTYMCS001222C36]; [@DOUGHERTYMCS001222C4]; [@DOUGHERTYMCS001222C13]; [@DOUGHERTYMCS001222C48]).

###### 

*NPC1* variants

  Gene symbol   Chromosome   HGVS DNA reference     HGVS protein reference   Variant type   dbSNP ID      Genotype       CADD score   ExAC MAF
  ------------- ------------ ---------------------- ------------------------ -------------- ------------- -------------- ------------ ----------
  *NPC1*        18           g.Chr18:21115443T\>C   p.N1156S                 Missense       rs28942105    Heterozygous   26.9         0.002
  *NPC1*        18           g.Chr18:21119382C\>T   p.V950M                  Missense       rs120074135   Heterozygous   12.2         0
  *NPC1*        18           g.Chr18:21119777G\>A   p.N931N                  Synonymous     rs1140458     Heterozygous   13.8         49.0
  *NPC1*        18           g.Chr18:21120444T\>C   p.I858V                  Missense       rs1805082     Heterozygous   17.2         49.5
  *NPC1*        18           g.Chr18:21124945C\>G   p.M642I                  Missense       n/a           Homozygous     6.6          71.8
  *NPC1*        18           g.Chr18:21140432T\>C   p.H215R                  Missense       rs1805081     Heterozygous   9.7          32.9
  *NPC1*        18           g.Chr18:21148863A\>G   p.Y129Y                  Synonymous     rs12970899    Heterozygous   8.8          14.4
  *NPC1*        18           g.Chr18:21166545G\>C                            5′ UTR         rs8099071     Heterozygous   8.3          n/a

All coding variants in *NPC1* identified in the patient along with one 5′-UTR variant. Coordinates are in GRCh37.

HGVS, Human Genome Variation Society; dbSNP, Database of Single-Nucleotide Polymorphisms; CADD score, Combined Annotation-Dependent Depletion Score; ExAc MAF, Exome Aggregation Consortium minor allele frequency out of 13,006 alleles; n/a, not available.

The patient\'s two pathogenic mutations are located in different domains of the NPC1 protein ([Fig. 1](#DOUGHERTYMCS001222F1){ref-type="fig"}). N1156S is located in the 11th of 13 transmembrane domains, in a region with homology to the patched family of proteins, and 43% sequence similarity to the sterol-sensing domain ([@DOUGHERTYMCS001222C10]; [@DOUGHERTYMCS001222C16]). V950M is located in the third large luminal loop, referred to as luminal domain I. Recent structural studies have shown that both luminal domain I and luminal domain C share a resemblance to the periplasmic porter domains of AcrB, part of the bacterial multidrug efflux pump ([@DOUGHERTYMCS001222C16]). Specifically, these domains are superimposable around a "core" region of tertiary structure conservation, and the mutated residue at V950M falls outside of this core region ([@DOUGHERTYMCS001222C16]). Interestingly, luminal domain I, also referred as the cysteine-rich loop, has been noted before for being the location of a number of mutations associated with late-onset disease or "variant" biochemical phenotype ([@DOUGHERTYMCS001222C28]; [@DOUGHERTYMCS001222C36]).

To prioritize variants found in the patient\'s genome outside of *NPC1*, we focused on mutations previously associated with similar neurological diseases, general longevity, and lipid metabolism. Although the etiology of NPC is distinct, the pathological and molecular similarities between NPC and other neurological diseases suggest that genetic modifiers to these more common diseases might also play a role in NPC pathogenesis ([@DOUGHERTYMCS001222C23]). Variants in *APOE* are strongly associated with both longevity and late-onset Alzheimer\'s disease ([@DOUGHERTYMCS001222C5]), and there is a possible link between ApoE status and disease pathology in NPC: Individuals with NPC who were homozygous for ApoE4 have shown diffuse amyloid-β plaques that correlated with extent of tauopathy ([@DOUGHERTYMCS001222C37]), and a study of 15 individuals with NPC demonstrated a correlation between ApoE2/ApoE4 status and the age of neurological onset ([@DOUGHERTYMCS001222C14]). However, both the patient and patient\'s brother were homozygous for the ApoE3 genotype, which is not associated with risk for Alzheimer\'s disease, so it is unlikely that the *APOE* locus played a significant role in the patients' disease progression.

Neurofibrillary tangles and aggregates of hyperphosphorylated tau protein are a pathological signature of NPC as well as other neurological diseases. Several studies in NPC knockout mice suggest a mechanistic role for tau in the pathogenesis of NPC, as a decrease in phosphorylated tau via inhibition of cyclin-dependent kinases improved NPC phenotypes ([@DOUGHERTYMCS001222C51]), whereas a complete knockout of the tau protein worsened the phenotypes ([@DOUGHERTYMCS001222C32]). Variation in *MAPT*, the gene encoding the tau protein, has been associated with both a faster rate of decline in Alzheimer\'s disease ([@DOUGHERTYMCS001222C18]) and risk for other neurodegenerative diseases associated with neurofibrillary tangle pathology ([@DOUGHERTYMCS001222C39]). The patient harbored no rare variants in *MAPT* and was negative for single-nucleotide polymorphisms (SNPs) associated with decreased levels of tau or phosphorylated tau in cerebrospinal fluid (rs3785883, rs8070723) ([@DOUGHERTYMCS001222C3]). Further, the patient was negative for known pathogenic mutations in genes associated with other lipid storage diseases.

Most loci associated with longevity are common variants with small effect sizes. The patient was found to have 21 of 39 SNPs associated with an increase in life span ([@DOUGHERTYMCS001222C22]; [@DOUGHERTYMCS001222C30]; [@DOUGHERTYMCS001222C50]; [@DOUGHERTYMCS001222C24]; [@DOUGHERTYMCS001222C43]; [@DOUGHERTYMCS001222C21]). Using the patient\'s variants and a published model, the patient had a predicted life span of 85 yr ([@DOUGHERTYMCS001222C43]). It is estimated that the genetic component of longevity in the Western World has been limited to survival beyond 85 yr, and it is therefore unlikely that many of these SNPs played a role in this NPC patient\'s late age of death ([@DOUGHERTYMCS001222C11]). Therefore, no definitive SNPs or overrepresentation of SNPs conferring either longevity or early mortality were identified in the patient\'s genome.

Finally, because the pathogenesis of NPC involves impaired cholesterol and lipid transport, we cross-referenced the patient\'s genome with the National Human Genome Research Institute--European Bioinformatics Institute (NHGRI-EBI) GWAS catalog to identify possible genetic modifiers in lipid metabolism pathways ([@DOUGHERTYMCS001222C46]). Several coding and noncoding SNPs associated with variation in blood cholesterol and triglyceride levels were found, but with mild effect sizes (Supplemental Table 1).

In addition to seeking potential genetic modifiers of the patient\'s disease course, we also assessed to what extent the patient\'s genome could have informed his diagnosis. Several tools have been created that attempt to incorporate genome sequence into clinical diagnosis. We tested one such tool, Phenolyzer (Phenotype-Based Gene Analyzer; [@DOUGHERTYMCS001222C49]), which integrates identified genomic variants with symptomology. Because NPC manifests differently according to the age of onset ([@DOUGHERTYMCS001222C33]), we created lists of common clinical terms associated with varying presentations (Supplemental Table 2). We then randomly downsampled these lists to five phenotypic terms, because the tool limits the number of allowed phenotypic inputs, and performed three permutations. The wANNOVAR-Phenolyzer pipeline ([@DOUGHERTYMCS001222C44]; [@DOUGHERTYMCS001222C7]; [@DOUGHERTYMCS001222C47]) performed best with queries sampled from infantile and childhood presentations, listing *NPC1* in the top five prioritized genes in five out of six queries and as the top gene in four out of six, most likely because of the specific phenotypes such as vertical supranuclear gaze palsy. Queries derived from the adult-onset presentation, with less specific phenotypic terms, did not perform as well. The requirement for the specific phenotypes, often associated with more infantile presentations, illustrates some of the challenges of trying to apply genetic sequence to less severe or stereotyped forms of Mendelian diseases, where both the effect of the mutations and clinical presentation may be less clear.

Phenotypic Analyses {#s2c}
-------------------

### Gross Neuropathologic Findings {#s2c1}

The whole fresh brain weighed 1280 g (1300 g fixed) and the fixed posterior fossa contents weighed 150 g. Evaluation of the dura revealed bilateral, holohemispheric, granular, orange subdural neomembranes (\<1-mm-thick) consistent with remote subdural hemorrhage. External examination of the brain showed mild frontal, temporal, and parietal cerebral cortical atrophy with unremarkable cerebellum and brainstem. Coronal sections of cerebral cortex were unremarkable other than mild hippocampal atrophy. Parasagittal sections of cerebellum revealed areas of mild folial atrophy with white matter thinning preferentially involving superior and, to a lesser extent, anterior cerebellar cortex. Axial sections of brainstem demonstrated moderate and mild pallor of the substantia nigra and locus coeruleus, respectively.

### Microscopic Findings {#s2c2}

Histologic examination ([Fig. 2](#DOUGHERTYMCS001222F2){ref-type="fig"}) of the brain tissue revealed numerous foam cells, including many balloon neurons, with abundant pale cytoplasm containing lightly eosinophilic granular storage material (light staining on periodic acid--Schiff \[PAS\] stain). Foam cells were found in the majority of the sampled gray matter with the highest density in the substantia nigra (\>50% of neuronal population), amygdala, striatum, and entorhinal and cingulate cortices. Variable numbers of foam cells were identified in all additional gray matter samples including cerebral isocortex, hippocampus, subiculum, nucleus basalis, paraventricular thalamus, cerebellar cortex (granular cell, Purkinje, and molecular layers), superior colliculi, oculomotor nerve nuclei, periaqueductal gray matter, locus coeruleus, dorsal pontine gray matter, medulla (including dorsal motor nucleus of the tenth cranial nerve), and rostral spinal cord. Numbers of gray matter lipofuscin or ceroid-laden neurons were increased for age and found in a similar distribution to foam cells (slightly darker staining with PAS). Microscopic analysis of the cerebellum revealed mild white matter atrophy with mild gliosis and extensive spans of Purkinje neuron loss (highlighted by calbindin immunohistochemistry) with Bergmann gliosis and numerous "empty baskets" (highlighted by Bielschowsky silver stain). Sections of cerebral cortex further demonstrated patchy, mild subcortical white matter myelin loss with variable mild gliosis and without significant cortical neuron loss (highlighted by glial fibrillary acid protein \[GFAP\] immunohistochemistry). These findings are consistent with previously reported structural changes associated with NPC ([@DOUGHERTYMCS001222C113]). Neurofibrillary tangle deposition, well characterized in NPC, was identified in the hippocampus, subiculum, entorhinal cortex, isocortex, and dentate fascia (indicative of Braak stage VI of VI). However, Alzheimer\'s disease pathology (i.e., amyloid-β plaques) was not identified (Thal stage 0, CERAD \[Consortium to Establish a Registry for Alzheimer\'s Disease\] 0). As such, the Braak score is not applicable. Other significant neuropathological findings include moderate loss of pigmented neurons in the substantia nigra and microscopically confirmed chronic subdural neomembranes. Finally, histologic examination was negative for evidence of Lewy body disease or cerebral microinfarcts.

![Pathological findings. (*A*) Hematoxylin and eosin (H&E) stain demonstrates scattered balloon neurons distended by lipid material in frontal cortex; Bielschowsky stain (*inset*) highlights frontal cortex balloon neuron. (*B*) Periodic acid--Schiff (PAS) stain highlights intracellular glycolipid in frontal cortex. (*C*) Tau-2 immunohistochemistry highlights neurofibrillary tangles in the subiculum. (*D*) H&E stain demonstrates Purkinje neuron loss with Bergmann gliosis. (*E*) Bielschowsky stain demonstrates numerous cerebellar "empty baskets." (*F*) Calbindin immunohistochemistry highlights widespread cerebellar Purkinje neuron/arbor loss.](DoughertyMCS001222_F2){#DOUGHERTYMCS001222F2}

DISCUSSION {#s3}
==========

We present what is to our knowledge the first full genome sequence of a patient with NPC. Although NPC has been long established as a recessive Mendelian disease, there is wide variability in both onset of disease and age at death ([@DOUGHERTYMCS001222C38]). The phenotypic variability may be caused by differences in the recessive alleles of *NPC* or modifiers elsewhere in the genome. In particular, the patient described here exhibited a level of NPC function greater than the average NPC patient and concomitantly a late eventual demise at age 54. WGS of the patient provided an unbiased method to detect potential modifiers and address the question of whether the genetic background might play a role in modulating the phenotype or if instead most of the difference can be accounted for by the variants in *NPC1* itself.

Both of the patient's putative causal variants (V950M and N1156S) have been previously seen in compound heterozygote cases of NPC ([@DOUGHERTYMCS001222C6]; [@DOUGHERTYMCS001222C13]; [@DOUGHERTYMCS001222C29]), although not reported together. That the V950M variant had been previously observed in multiple individuals with the adult-onset phenotype is consistent with its being a hypomorphic allele, whose partial function contributes to both the variant NPC biochemical phenotype and the somewhat later onset and late age at death. Previously, when V950M has been observed in cases of adult-onset NPC, it was either a homozygous mutation or compound heterozygous with I1061T, an allele associated with juvenile-onset NPC. In contrast, the N1156S variant has been observed in severe infantile disease. The observation of the V950M variant paired with N1156S suggests that a single copy of a hypomorphic *NPC1* gene provides sufficient function for delayed onset of disease.

One obstacle in interpreting WGS data is identifying genes of interest. In this analysis, we took a simple approach of focusing on genes involved in pathways affected in NPC or linked to similar neurological phenotypes. Looking at the pathways affected in NPC, the patient harbored variants associated with both increased and decreased lipid levels. Although four out of five variants are associated with increased levels, the patient is homozygous for a missense variant in *APOB* with the strongest effect, a decrease in trigylcerides of 5.99 mg/dL. However, it is hard to say whether or not these could have impacted the patient\'s clinical outcome. The patient was negative for variants strongly associated with either neurodegenerative disease or longevity. In particular, for *APOE*---perhaps the best candidate for a gene with a common, high-impact variant---the patient carried the most common ApoE3 variant, which is not associated with increased life span. All together, we found no compelling evidence of strong genetic modifiers outside of the *NPC1* gene. This is consistent with the relative mildness of the V950M variant being the main contributor to the patient\'s phenotype.

The patient\'s clinical history speaks to the diagnostic challenges that present even with well-characterized genetic diseases. As genomic techniques have become increasingly more common and cost-effective, this type of analysis is coming ever closer to clinical use. An important question with this approach is whether the information gained through WGS could have made an impact on the patient\'s care had it been performed while he was still alive.

Novel variants in disease genes can be difficult to interpret. In the patient described here, both variants had been previously observed and as such were already presumed to be causal. We may ask, however, how they would have been interpreted were they not seen before in NPC patients. Metrics like conservation, allele frequency, or type of amino acid change can be used to predict the effect of a novel mutation. Newer supervised machine learning approaches have been used to integrate many of these simultaneously. Applied to these variants, commonly used bioinformatics tools like PolyPhen (Polymorphism Phenotyping; [@DOUGHERTYMCS001222C2]) and CADD (Combined Annotation-Dependent Depletion; [@DOUGHERTYMCS001222C19]) highlight the N1156S mutation as likely damaging: A PolyPhen score of 1 ("possibly damaging") and a CADD score of 26.9 provide supporting but not overwhelming evidence for the deleteriousness of this variant. However, for the V950M mutation, conservation does not provide strong evidence for disruption of function as a PolyPhen score of 0.007 and a CADD score of 12.2 are low enough such that this variant would likely fail to pass common filtering steps for identifying deleterious missense variants if it had not been previously identified as a disease-causing mutation. In particular, this highlights the challenge in predicting pathogenicity of variants responsible for milder forms of inherited disease, where the impact of the causal variants on gene function may be more subtle. Although it is not possible to draw definitive conclusions from an *N* = 1 case study, given the role rare, high-impact, variants play in human disease and disease modifiers ([@DOUGHERTYMCS001222C8]), case-only sequencing of patients with atypical phenotypes has the potential to discover novel variants in disease-associated pathways that may play a role in disease pathology. This approach has limited power, especially for detecting low-effect size variants, but is realistic in clinical scenarios when family pedigrees and tissue samples are not available or consent cannot be obtained.

Finally, sequencing and analysis of this patient was done in conjunction with a course for first-year students in a Medical Scientist Training Program. With the ever-growing promise of precision medicine and increasing use of genomic technologies in the clinic, WGS and interpretation allows students to explore both its utility and challenges. We hope this class may serve as a model for the possibilities created by integrating this type of patient analysis into medical education ([@DOUGHERTYMCS001222C20]). In this course, students took responsibility for every aspect of the study, including the clinical history, gross anatomical dissection, and microscopic analysis of the brain, analysis of sequencing data, and preparation of the manuscript. In addition to furthering our understanding of NPC etiology, we believe that this course and ones like it have the potential for great didactic value for the development of future physicians and scientists.

METHODS {#s4}
=======

Gross Neuropathological Analysis {#s4a}
--------------------------------

Formalin-fixed brain tissue was sectioned into 4-mm-thick slices (brain, coronal; cerebellum, parasagittal; brainstem, axial) for gross examination. Tissue sections were submitted according to 2012 NIA-AA (National Institute on Aging-Alzheimer\'s Association) criteria with submission of additional tissue sections to demonstrate NPC pathology.

Microscopic Analysis {#s4b}
--------------------

Microscopic slides were prepared from each of the tissue sections. All sections were stained with hematoxylin and eosin/luxol fast blue (H&E/LFB) with targeted performance of the following immunohistochemical and histochemical stains: amyloid-β (AE10), tau-2, α-synuclein, glial fibrillary acidic protein (GFAP), calbindin, myelin basic protein (MBP), NeuN, CD68, Bielschowsky modified silver, and Congo Red.

Sample Collection {#s4c}
-----------------

Fresh cerebellar tissue was frozen at the time of autopsy while the remainder of the brain was fixed in formalin for histological sampling.

Genomic Sequencing and Analysis {#s4d}
-------------------------------

DNA was extracted from 70 µg frozen cerebellum using QIAGEN DNeasy Blood & Tissue Kit. Shotgun sequencing libraries were prepared using the KAPA library preparation kit (Kapa Biosystems) following manufacturer\'s instructions. The library sample was sequenced to 50× coverage on an Illumina NextSeq with 150-bp paired-end reads and mapped to GRCh37/hg19 (see Supplemental Table 3 for coverage). SNVs and small indels were called using Genome Analysis Toolkit (GATK) following best practices ([@DOUGHERTYMCS001222C26]; [@DOUGHERTYMCS001222C12]) and variants were annotated with SeattleSeq ([@DOUGHERTYMCS001222C31]). We identified 3.3 million SNVs with a transition to transversion ratio of 2.08. Of these, 20,271 were protein-coding mutations, and 1318 of the protein-coding mutations were rare variants (observed in \<1% of samples from the Exome Variant Server). We also detected 561,488 small indels with 526 falling in coding regions.

Sanger Sequencing of Patient\'s Brother {#s4e}
---------------------------------------

Genomic DNA was isolated from the patient\'s brother. The V950M and N1156S mutations were amplified and sequenced with the following primers: V950MF: 5′-GTAAAGGAGAAGGTACCTGAAGCATTGC-3′V950MR: 5′-ACTAAAGACTTCCTCCCTGTGGAGCAG-3′N1156SF: 5′-CAAGCGCCAGACTTGGTATCTTACTCC-3′N1156SR: 5′-TGTGAGCTCTGGTCTGCAGTCATCATG-3′

The ApoE genotype of the patient\'s brother was amplified and sequenced with the following primers: ApoE1F: 5′-GCTGATGGACGAGACCATGAAGGAG-3′ApoE1R: 5′-GCAGGCCATGCTCGGCCAGAGCACC-3′ApoE2F: 5′-TGCAGGTCATCGGCATCGCGGAGGAG-3′ApoE2R: 5′-CACCTGCTCCTTCACCTCGTCCAGG-3′

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

Patient consent was not explicitly obtained for depositing whole-genome sequencing data in an external archive. Requests for data access can be brought to our institutional review board (IRB). Please direct inquiries to Max Dougherty (<mldough@uw.edu>), John Lazar (<jlazar@uw.edu>), and Jason Klein (<jcklein@uw.edu>). The two *NPC1* causal variants (V950M and N1156S) have been deposited to ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) under accession numbers SCV000297807 and SCV000297806, respectively.

Ethics Statement {#s5b}
----------------

The patient was a participant in the University of Washington Alzheimer\'s Disease Research Center (ADRC) Clinical Core research program. Participation requires prior written consent by the patient with either written or witnessed verbal confirmation of consent by legal next of kin upon the patient\'s death. Brain autopsy consent specifies that brain tissue removed at autopsy may be retained and used for educational, scientific, and research purposes. A separate brain bank tissue banking consent is also obtained. The University of Washington IRB determined that this research and related tissue banking involving preconsented deceased individuals is not considered human subjects research according to 45 CFR 46.102(f) and, therefore, exempt from IRB review.
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